Changchun High-Tech Industry (Group) Co.,Ltd. (000661.SZ) has announced that its subsidiary, Changchun GeneScience Pharmaceutical Co., Ltd. ("GeneScience Pharmaceutical"), has received a Drug Clinical Trial Approval Notice issued by the National Medical Products Administration.
The domestic production drug registration clinical trial application for GeneScience Pharmaceutical's GenSci136 for Injection has been approved.
GenSci136 for Injection is a BAFF/APRIL dual-target antagonist independently developed by GeneScience Pharmaceutical, classified as a Class 1 therapeutic biological product for registration in China, and is intended for the treatment of systemic lupus erythematosus (SLE).
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.